Ways of Regulating Drugs in the 19th and 20th Centuries / Science, Technology and Medicine in Modern History (PDF)

CHRISTIAN BONAH Professor for the History of Medical and Health Sciences at the University of Strasbourg, France
ALBERTO CAMBROSIO Professor in the Department of Social Studies of Medicine at McGill University, Canada
MAURICE CASSIER Sociologist and a Senior Researcher for the National Centre for Scientific Research (CNRS), France
JEREMY GREENE Assistant Professor of the History of Science at Harvard University, USA
AXEL C. HÜNTELMANN Academic Assistant at the Institute for the History Theory and Ethics of Medicine at the Gutenberg University in Mainz, Germany
PETER KEATING Professor of History at the Université du Québec à Montréal, Canada
ILANA LÖWY Senior Researcher at INSERM (Institut National de la Santé et de la Recherche Scientifique), Paris, France
HARRY M. MARKS was Associate Professor at the Institute of the History of Medicine, Johns Hopkins University, USA
DONNA A. MESSNER Research Director at the Center for Medical Technology Policy in Baltimore, USA
TOINE PIETERS Professor of the History of Pharmacy at Utrecht University, the Netherlands
VIVIANE QUIRKE RCUK Academic Fellow and Senior Lecturer in Modern History and History at Oxford Brookes University, UK
STEPHEN SNELDERS Research Fellow at the Descartes Centre for the History and Philosophy of the Sciences and the Humanities at Utrecht University, the Netherlands

"Ways of Regulating Drugs presents twelve very wide-ranging, generally excellent, and often quite specialized chapters. ... This is all thought-provoking, quality work. The 'ways of regulating' framework brings wonderfully sophisticated analysis to the history of drug regulation, especially when focused on state, industrial, professional, and juridical actors whose power to create and enforce is evident." - David Herzberg, University at Buffalo, USA

"Ways of Regulating Drugs offers a stimulating history of the pharmaceutical products and industry during the 19th and 20th century. The choice of the authors is to assume different ways of analysing drug trajectories the demonstration is really convincing: it shows that if drugs aren't like other goods and if public health refers to a specific market, their history might not remain at the frontiers of the history of sciences, economic history or political history. The question of drug trajectories and of their regulations has become crucial enough to be liable to resolutely and fruitful multidisciplinary approaches, of which this book is a major issue." - Sophie Chauveau, Gesnerus, 71, (2014)